The use of multi-domain patient reported outcome measures for detecting clinical disease progression in multiple sclerosis.

Disability tests Disease progression Guy's neurological disability scale Leg function Multiple sclerosis impact scale Patient reported outcome measures Progressive multiple sclerosis

Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Oct 2021
Historique:
received: 28 04 2021
revised: 17 07 2021
accepted: 22 07 2021
pubmed: 18 8 2021
medline: 21 10 2021
entrez: 17 8 2021
Statut: ppublish

Résumé

Patient reported outcome measures (PROMs) are especially relevant in times of increased interest in telehealth but little is known about their relation to functional disability measures. We assessed 248 people with MS at baseline and at > = 5-years follow-up. We investigated cross-sectional and longitudinal correlations between changes in the Guy's Neurological disability scale (GNDS), and the physical part of the Multiple Sclerosis Impact Scale (MSIS-29) and the Expanded Disability Status Scale (EDSS), 9-hole peg test (9-HPT) and timed 25-foot walk (T25FW). The strongest cross-sectional correlations were found between the GNDS and EDSS in the complete cohort (r = 0.66, p <.001, n = 248) as well as in progressive patients (r = 0.72, p <.001, n = 35), and the GNDS and T25FW in progressive MS (r = 0.64, p <.001, n = 34). Longitudinal correlations were poor except for changes on the leg domain of the GNDS in relation to T25FW changes in progressive MS (r = 0.68, p <.001, n = 26). In the majority of cases a clinically significant deterioration on the EDSS also resulted in a clinically significant worsening of the GDNS and MSIS. Both PROMs correlate well with physical disability outcomes, and seem suitable for detecting changes in lower limb function in progressive MS. The GNDS has a higher agreement with EDSS progression than the MSIS-physical.

Identifiants

pubmed: 34404022
pii: S2211-0348(21)00432-6
doi: 10.1016/j.msard.2021.103165
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103165

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Auteurs

C A A van 't Hullenaar (CAA)

Dept. of Neurology, Haaglanden Medisch Centrum, Den Haag, Netherlands; Dept. of Neurology, Amsterdam UMC, location VUmc. Amsterdam, Netherlands.

E Coerver (E)

Dept. of Neurology, Amsterdam UMC, location VUmc. Amsterdam, Netherlands.

N F Kalkers (NF)

Dept. of Neurology, Amsterdam UMC, location VUmc. Amsterdam, Netherlands; Dept. of Neurology, OLVG West & Oost, Amsterdam, Netherlands.

Z van Kempen (Z)

Dept. of Neurology, Amsterdam UMC, location VUmc. Amsterdam, Netherlands.

M Koch (M)

Dept. of Clinical Neurosciences, University of Calgary, Calgary, Canada.

B M J Uitdehaag (BMJ)

Dept. of Neurology, Amsterdam UMC, location VUmc. Amsterdam, Netherlands.

J Killestein (J)

Dept. of Neurology, Amsterdam UMC, location VUmc. Amsterdam, Netherlands.

E M M Strijbis (EMM)

Dept. of Neurology, Amsterdam UMC, location VUmc. Amsterdam, Netherlands. Electronic address: E.strijbis@amsterdamumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH